Overview

This trial is active, not recruiting.

Conditions leukemia, acute myeloid, leukemia, lymphoblastic,acute, myelodysplastic syndromes
Treatment brentuximab vedotin
Phase phase 0
Sponsor Washington University School of Medicine
Start date February 2013
End date November 2015
Trial size 17 participants
Trial identifier NCT01700751, 201211047

Summary

This pilot clinical trial studies the safety and maximum tolerated dose of brentuximab vedotin when given with tacrolimus and methotrexate after unrelated allogeneic donor stem cell transplant in patients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes. The addition of brentuximab vedotin to tacrolimus and methotrexate may result in a significant reduction of graft versus host disease in these patients.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
brentuximab vedotin 0.3mg/kg, given IV on Days 7, 28, 49 & 70
brentuximab vedotin Adcetris
(Experimental)
brentuximab vedotin 0.6mg/kg, given IV on Days 7, 28, 49 & 70
brentuximab vedotin Adcetris
(Experimental)
brentuximab vedotin 1.2mg/kg, given IV on Days 7, 28, 49 & 70
brentuximab vedotin Adcetris
(Experimental)
brentuximab vedotin 1.8mg/kg, given IV on Days 7, 28, 49 & 70
brentuximab vedotin Adcetris
(No Intervention)
The first 3 patients will not receive brentuximab vedotin.

Primary Outcomes

Measure
MTD of brentuximab vedotin when administered with a GVHD prophylaxis regimen
time frame: 37 days

Secondary Outcomes

Measure
Safety and tolerability of brentuximab vedotin when administered with a GVHD prophylaxis regimen
time frame: 100 days
Rate of acute GVHD
time frame: 100 days
Rate of chronic GVHD
time frame: 2 years
Progression-free survival
time frame: 2 years
Overall survival.
time frame: 2 years
1-year non-relapse mortality rate
time frame: 1 year
2-year non-relapse mortality rate
time frame: 2 years
1-year disease relapse rate
time frame: 1 year
2-year disease relapse rate
time frame: 2 years

Eligibility Criteria

Male or female participants from 18 years up to 70 years old.

Inclusion Criteria: - Patient must be scheduled to undergo stem cell transplantation for one of the following diagnoses: - acute myeloid leukemia (AML) in CR1 (first complete remission, CR or CRi) or CR2 (second complete remission, CR or CRi), - acute lymphoblastic leukemia (ALL) in CR1 or CR2 (CR or CRi) - myelodysplastic syndrome (MDS) without progression to AML. - Chronic myelogenous leukemia (CML) - Non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) - Chronic lymphocytic leukemia (CLL) - Multiple myeloma (MM) - Patients must be the recipient of unrelated donor peripheral blood stem cell products. Mismatches at both antigen and allele level will be eligible. Match must be 6 or 7 out of 8 loci (HLA A, B, C, and DRB1). - Patient must receive any one of the following conditioning regimens: total body radiation (single or fractionated dose)/cyclophosphamide, busulfan/ cyclophosphamide, or fludarabine/busulfan/lymphocyte immune globulin (ATGAM/thymo). - Patient must be ≥ 18 years and ≤ 70 years of age. - Patient must have an ECOG performance status ≤ 2 or Karnofsky performance scale ≥ 60% - Patient must have CD34+ stem cells ≥ 2x106/kg (actual body weight of the recipient) available for transplantation. - Patient must have appropriate organ function as defined below (this criterion should be met on screening and on the day of the first dose of brentuximab vedotin (as assessed prior to dosing)): - Total bilirubin ≤ 2.0 x IULN - AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN - Serum creatinine ≤ 2.0 x IULN - Estimated Creatinine Clearance > 30 ml/min - Cardiac ejection fraction > 40% - DLCO/VA > 40% - Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. - Patient must be able to understand and willing to sign an IRB approved written informed consent document. Exclusion Criteria: - Patient must not have had prior exposure to brentuximab vedotin. - Patient must not have a history of other malignancy that has not been in remission for at least 3 years, with the exception of basal non-melanoma skin cancer which were treated with local resection only or intraepithelial lesions or carcinoma in situ of the cervix or prostate that has been curatively treated. - Patient must not be receiving any other investigational agents. - Patient must not have active CNS involvement. - Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab vedotin or other agents used in the study. - Patients must not have had previous radiation therapy to the mediastinum or lungs. - Patient must not have an uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active pulmonary diseases, or psychiatric illness/social situations that would limit compliance with study requirements (this criterion should be met on screening and on the day of but prior to first dose of brentuximab vedotin). - Patient must not be pregnant and/or breastfeeding. - Patient must not be known to be HIV-positive on combination antiretroviral therapies. - Patient must not have had a previous allogeneic or syngeneic transplant. Prior autologous transplant is allowed.

Additional Information

Official title A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
Principal investigator Mark Schroeder, M.D.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Washington University School of Medicine.